- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05326750
Ikke-invasiv neurostimulation som et værktøj til diagnostik og behandling af neurodegenerative sygdomme
Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Eino Solje, MD, PhD
- Telefonnummer: +358 17 713 311
- E-mail: eino.solje@uef.fi
Studiesteder
-
-
-
Kuopio, Finland
- Rekruttering
- Kuopio University Hospital
-
Kontakt:
- Eino Solje
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Mild Cognitive Impairment due to Alzheimer's disease
- Dementia with Lewy Bodies
- Frontotemporal dementia
- Idiopathic normal pressure hydrocephalus (iNPH)
Exclusion Criteria:
- History of seizures
- Pregnancy
- Metal implants in the head (except dental fillings)
- Electronic implants (i.e. pace-maker, implanted medical pump)
- Age <18 years
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Real tACS
Four sessions (once a day, during four consecutive days) of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus) |
Single session of gamma tACS (40 Hz) over the superior parietal cortex |
|
Placebo komparator: Sham tACS
Four sessions of sham tACS (once a day, during four consecutive days) over the superior parietal cortex (Precuneus) |
Single session of gamma tACS (40 Hz) over the superior parietal cortex |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes in Rey Auditory Verbal Learning Test score
Tidsramme: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. Another list of 15 unrelated words are given and the patient must again repeat the original list of 15 words and then again after 30 minutes. The examiner reads aloud 15 unrelated words and the participant is asked to recall the words after each of the five trials. After a 15 minute delay, the participant is asked again to recall the words. The score ranges from 0 (worst performance) to 75 (best performance). |
Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
|
Changes in Rey Auditory Verbal Learning Test, recognition
Tidsramme: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. After a 15 minute delay, the participant is asked to recognise the original 15 words intermixed with 31 distractor words. The score of the recognition part ranges from 0 (worst performance) to 46 (best performance). |
Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
|
Changes in orientation to time and place (MMSE questions 1-10)
Tidsramme: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
10 questions about the orientation. The score ranges from 0 (worse performance) to 10 (best performance). |
Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
|
Changes in Trail Making A & B tests
Tidsramme: Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
|
TMT A & B tests. Time to perform set is recorded. |
Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
|
|
Changes in INECO Frontal Screening test
Tidsramme: Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
|
Test battery assessing frontal lobe functions. The score ranges from 0 (worse performance) to 30 (best performance) |
Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
|
|
Changes in phonemic fluency
Tidsramme: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
Person is requested to provide as many words as possible starting with certain letter. The score is the sum of all acceptable words produced in one minute. |
Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in SAI measurements
Tidsramme: Baseline (immediately before the intervention), immediately after the last intervention
|
By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short latency afferent inhibition (SAI), which is a marker of cholinergic neurotransmission. |
Baseline (immediately before the intervention), immediately after the last intervention
|
|
Change in SICI measurements
Tidsramme: Baseline (immediately before the intervention), immediately after the last intervention
|
By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short interval intracortical inhibition (SICI), which is a marker of gabaergic neurotransmission. |
Baseline (immediately before the intervention), immediately after the last intervention
|
|
Change in ICF measurements
Tidsramme: Baseline (immediately before the intervention), immediately after the last intervention
|
By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on intracortical facilitation (ICF), which is a marker of glutamatergic neurotransmission. |
Baseline (immediately before the intervention), immediately after the last intervention
|
|
Change in modified Frontal Behavioral Inventory (FBI-mod) score
Tidsramme: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
The modified Frontal Behavioral Inventory (FBI-mod) is used to assess behavioral symptoms associated with frontotemporal dysfunction. The questionnaire evaluates changes in behavioral and personality features. Higher scores indicate a greater severity of behavioral symptoms. |
Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
|
Change in Neuropsychiatric Inventory (NPI) score
Tidsramme: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
The Neuropsychiatric Inventory (NPI) is used to assess neuropsychiatric symptoms, including their frequency and severity. Higher total scores indicate a greater burden of neuropsychiatric symptoms. |
Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Eino Solje, MD, PhD, Kuopio University Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Synukleinopatier
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Psykiske lidelser
- Metaboliske sygdomme
- Neurokognitive lidelser
- Demens
- Tauopatier
- Neurodegenerative sygdomme
- Bevægelsesforstyrrelser
- Parkinsonlidelser
- Basal Ganglia Sygdomme
- TDP-43 Proteinopatier
- Proteostase mangler
- Frontotemporal Lobar Degeneration
- Ernæringsmæssige og metaboliske sygdomme
- Alzheimers sygdom
- Frontotemporal demens
- Lewy Body sygdom
Andre undersøgelses-id-numre
- KUH5772859
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Pseudonymized data upon request, according to Finnish national and EU GDPR regulations
IPD-delingstidsramme
Data will be shared after the study completion indefinitely.
IPD-delingsadgangskriterier
Reasonable request
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .